{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:14:33Z","timestamp":1771953273716,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10147-019-01523-w","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T10:02:50Z","timestamp":1565604170000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Yukiharu","family":"Hiyoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kiyozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"1523_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/014107688808100904","volume":"81","author":"RJ Heald","year":"1988","unstructured":"Heald RJ (1988) The 'Holy Plane' of rectal surgery. J R Soc Med 81:503\u2013508","journal-title":"J R Soc Med"},{"key":"1523_CR2","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731\u20131740","journal-title":"N Engl J Med"},{"key":"1523_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ijrobp.2009.03.010","volume":"76","author":"K Bruheim","year":"2010","unstructured":"Bruheim K, Guren MG, Skovlund E et al (2010) Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76:1005\u20131011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1523_CR4","first-page":"1789","volume":"18","author":"DA Rothenberger","year":"2004","unstructured":"Rothenberger DA, Akbari R, Baxter NN (2004) Are we overtreating some patients with rectal cancer? Oncology 18:1789\u20131796","journal-title":"Oncology"},{"key":"1523_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","volume":"23","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1\u201334","journal-title":"Int J Clin Oncol"},{"key":"1523_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/bjs.4350","volume":"90","author":"S Fujita","year":"2003","unstructured":"Fujita S, Yamamoto S, Akasu T et al (2003) Lateral pelvic lymph node dissection for advanced lower rectal cancer. Br J Surg 90:1580\u20131585","journal-title":"Br J Surg"},{"key":"1523_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/bjs.4975","volume":"92","author":"M Ueno","year":"2005","unstructured":"Ueno M, Oya M, Azekura K et al (2005) Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg 92:756\u2013763","journal-title":"Br J Surg"},{"key":"1523_CR8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s10350-006-0714-z","volume":"49","author":"K Sugihara","year":"2006","unstructured":"Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663\u20131672","journal-title":"Dis Colon Rectum"},{"key":"1523_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/SLA.0000000000002212","volume":"266","author":"S Fujita","year":"2017","unstructured":"Fujita S, Mizusawa J, Kanemitsu Y et al (2017) Mesorectal excision with or without lateral lymph node dissection for clinical stage II\/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg 266:201\u2013207","journal-title":"Ann Surg"},{"key":"1523_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/BF02553825","volume":"32","author":"K Hojo","year":"1989","unstructured":"Hojo K, Sawada T, Moriya Y (1989) An analysis of survival and voiding, sexual function after wide iliopelvic lymphadenectomy in patients with carcinoma of the rectum, compared with conventional lymphadenectomy. Dis Colon Rectum 32:128\u2013133","journal-title":"Dis Colon Rectum"},{"key":"1523_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00384-009-0704-4","volume":"24","author":"S Fujita","year":"2009","unstructured":"Fujita S, Yamamoto S, Akasu T et al (2009) Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Colorectal Dis 24:1085\u20131090","journal-title":"Int J Colorectal Dis"},{"key":"1523_CR12","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1245\/s10434-017-6069-y","volume":"24","author":"Y Miyake","year":"2017","unstructured":"Miyake Y, Mizushima T, Hata T et al (2017) Inspection of perirectal lymph nodes by one-step nucleic acid amplification predicts lateral lymph node metastasis in advanced rectal cancer. Ann Surg Oncol 24:3850\u20133856","journal-title":"Ann Surg Oncol"},{"key":"1523_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/bjs.5665","volume":"94","author":"H Yano","year":"2007","unstructured":"Yano H, Saito Y, Takeshita E et al (2007) Prediction of lateral pelvic node involvement in low rectal cancer by conventional computed tomography. Br J Surg 94:1014\u20131019","journal-title":"Br J Surg"},{"key":"1523_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023\u20131034","journal-title":"N Engl J Med"},{"key":"1523_CR15","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"1523_CR16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"1523_CR17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011\u20132019","journal-title":"J Clin Oncol"},{"key":"1523_CR18","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"1523_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"1523_CR20","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"1523_CR21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","volume":"27","author":"R Adam","year":"2009","unstructured":"Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829\u20131835","journal-title":"J Clin Oncol"},{"key":"1523_CR22","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575\u20134580","journal-title":"J Clin Oncol"},{"key":"1523_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00280-014-2417-9","volume":"73","author":"J Hasegawa","year":"2014","unstructured":"Hasegawa J, Nishimura J, Mizushima T et al (2014) Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol 73:1079\u20131087","journal-title":"Cancer Chemother Pharmacol"},{"key":"1523_CR24","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1245\/s10434-017-5967-3","volume":"24","author":"S Hasegawa","year":"2017","unstructured":"Hasegawa S, Goto S, Matsumoto T et al (2017) A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Ann Surg Oncol 24:3587\u20133595","journal-title":"Ann Surg Oncol"},{"key":"1523_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","volume":"32","author":"D Schrag","year":"2014","unstructured":"Schrag D, Weiser MR, Goodman KA et al (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32:513\u2013518","journal-title":"J Clin Oncol"},{"key":"1523_CR26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/jjco\/hyt115","volume":"43","author":"K Uehara","year":"2013","unstructured":"Uehara K, Hiramatsu K, Maeda A et al (2013) Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial. Jpn J Clin Oncol 43:964\u2013971","journal-title":"Jpn J Clin Oncol"},{"key":"1523_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00595-014-0906-4","volume":"45","author":"T Furuhata","year":"2015","unstructured":"Furuhata T, Okita K, Nishidate T et al (2015) Clinical feasibility of laparoscopic lateral pelvic lymph node dissection following total mesorectal excision for advanced rectal cancer. Surg Today 45:310\u2013314","journal-title":"Surg Today"},{"key":"1523_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1245\/s10434-010-1238-2","volume":"18","author":"JT Liang","year":"2011","unstructured":"Liang JT (2011) Technical feasibility of laparoscopic lateral pelvic lymph node dissection for patients with low rectal cancer after concurrent chemoradiation therapy. Ann Surg Oncol 18:153\u2013159","journal-title":"Ann Surg Oncol"},{"key":"1523_CR29","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00464-015-4418-0","volume":"30","author":"K Nagayoshi","year":"2016","unstructured":"Nagayoshi K, Ueki T, Manabe T et al (2016) Laparoscopic lateral pelvic lymph node dissection is achievable and offers advantages as a minimally invasive surgery over the open approach. Surg Endosc 30:1938\u20131947","journal-title":"Surg Endosc"},{"key":"1523_CR30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00268-016-3762-0","volume":"41","author":"A Ogura","year":"2017","unstructured":"Ogura A, Akiyoshi T, Nagasaki T et al (2017) Feasibility of laparoscopic total mesorectal excision with extended lateral pelvic lymph node dissection for advanced lower rectal cancer after preoperative chemoradiotherapy. World J Surg 41:868\u2013875","journal-title":"World J Surg"},{"key":"1523_CR31","first-page":"3529","volume":"27","author":"H Matsuoka","year":"2007","unstructured":"Matsuoka H, Nakamura A, Masaki T et al (2007) Optimal diagnostic criteria for lateral pelvic lymph node metastasis in rectal carcinoma. Anticancer Res 27:3529\u20133533","journal-title":"Anticancer Res"},{"key":"1523_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/01.sla.0000225359.72553.8c","volume":"245","author":"H Ueno","year":"2007","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2007) Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg 245:80\u201387","journal-title":"Ann Surg"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01523-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T23:45:43Z","timestamp":1597103143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01523-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01523-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"20 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}